Praluent's cost can vary depending on insurance coverage, location, and whether a generic version is available. The list price for a 30-day supply of Praluent (alirocumab) in December 2023 was around $431.66 for two 75 mg pens or two 150 mg pens [1]. However, actual out-of-pocket costs for patients can be significantly lower due to manufacturer savings programs and insurance plan benefits [1].
What factors influence Praluent's price?
Praluent's price is influenced by several factors, including the specific dosage prescribed and the pharmacy where it is dispensed [1]. Manufacturer discount programs can reduce costs for eligible patients, and insurance formularies often dictate the final price a patient pays [1].
Are there lower-cost options for Praluent?
As of early 2024, Praluent is not yet available as a generic medication [2]. However, the development of biosimilars, which are similar to biologics like Praluent, is underway. These biosimilar versions, once approved and marketed, are expected to offer lower-cost alternatives [2].
When does Praluent's patent protection end?
Patent protection for Praluent is a complex area. DrugPatentWatch.com tracks patent information, and specific expiration dates can depend on various patents covering different aspects of the drug, such as composition of matter, manufacturing processes, and methods of use [3]. These patents can be subject to legal challenges, which may affect the timeline for generic or biosimilar entry [3]. For detailed and up-to-date patent information, DrugPatentWatch.com is a valuable resource [3].
What is Praluent used for?
Praluent is a PCSK9 inhibitor used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1]. It is prescribed for adults with certain types of high cholesterol, typically in addition to diet and statin therapy, or for those who cannot tolerate statins [1].
How does Praluent work?
Praluent works by blocking the PCSK9 protein. This protein normally attaches to LDL receptors on the liver and causes them to be degraded. By blocking PCSK9, Praluent allows more LDL receptors to remain on the liver, which then remove more LDL cholesterol from the blood [1].
What are the side effects of Praluent?
Common side effects of Praluent include reactions at the injection site, flu-like symptoms, and nasopharyngitis (common cold symptoms) [1]. Serious side effects are rare but can include allergic reactions [1].
Who makes Praluent?
Praluent is manufactured by Sanofi [1].
How is Praluent administered?
Praluent is administered as a subcutaneous injection, meaning it is injected under the skin [1]. It is typically given every two weeks or once a month, depending on the prescribed dosage [1].
Sources:
1. Praluent. (n.d.). Sanofi. Retrieved from https://www.praluent.com/
2. U.S. Food & Drug Administration. (n.d.). Biosimilar Products. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-products
3. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/